(917) 310-3371
Nuzolvence is the oral antibiotic zoliflodacin, FDA-approved in December 2025 for uncomplicated urogenital gonorrhea. It is supplied as granules mixed into an oral suspension and taken as a single prescribed treatment.
Review all positive infection sites and confirm that the prescription addresses uncomplicated urogenital gonorrhea. Provide a measured weight, pregnancy information, allergies and every medicine, particularly CYP3A4 inducers. Pregnancy testing is required for patients who can become pregnant, and the male-partner contraception advice extends for 90 days after treatment when applicable. Food instructions change at 50 kg, so obtain the correct instructions rather than following another patient's experience. Use the packet only as directed and contact the service for a preparation error or vomiting. Arrange partner care and any additional infection treatment.
Nuzolvence is the oral antibiotic zoliflodacin, FDA-approved in December 2025 for uncomplicated urogenital gonorrhea. It is supplied as granules mixed into an oral suspension and taken as a single prescribed treatment. This indication is specific: it does not establish the medicine as treatment for throat, rectal or disseminated gonorrhea. A clinician must identify the infection sites and review safety before choosing it.
Zoliflodacin inhibits a bacterial enzyme involved in DNA replication. It treats gonorrhea rather than preventing future infection. An oral formulation may be useful for some patients, but convenience alone does not determine suitability. It does not automatically treat chlamydia or other causes of discharge, and it does not replace HIV or syphilis testing when those are indicated.
The labeled population includes adults and adolescents aged 12 or older weighing at least 35 kg with uncomplicated urogenital gonorrhea. A known allergy to the medicine and concurrent moderate or strong CYP3A4 inducers are contraindications. Pregnancy must be assessed: the label calls for a pregnancy test in patients who can become pregnant and warns of fetal harm based on animal data. Infection site, pregnancy, weight, interacting medicines and other treatment options affect the decision.
Tell the clinician about vaginal, oral and anal exposures and symptoms. Genital, throat and rectal tests may be needed. Fever, severe pelvic pain, testicular pain or a painful swollen joint requires assessment for complications.
Bring all prescription drugs, supplements and herbs. Discuss pregnancy testing, contraception and fertility concerns before treatment. A medicine that changes drug metabolism can make zoliflodacin unsuitable.
The prescribed treatment uses a single packet prepared with water. Food instructions depend on weight: patients from 35 to under 50 kg take it on an empty stomach, while those at least 50 kg take it with food. Follow the supplied instructions; do not substitute other liquids or estimate the dose.
Obtain a plan for any other infection detected, treatment of partners, avoiding sex during the post-treatment interval and retesting. Persistent symptoms require reassessment rather than another self-administered packet.
Bring prior tests, exposure dates and the full medication list. Confirm a pregnancy test and explain whether you or a partner may become pregnant. The label advises males with female partners of reproductive potential to use effective contraception for at least 90 days after treatment. It also describes potential testicular and fertility harms based on animal data; an assessment of spermatogenesis has not been performed in humans. Discuss those uncertainties rather than treating them as proven infertility or dismissing them.
Headache, dizziness, nausea and diarrhea were among reported adverse effects. Call 911 for trouble breathing, facial swelling or a severe allergic reaction. If you vomit, cannot finish the prepared medicine or have a preparation error, contact the prescriber or pharmacist promptly. Do not decide yourself whether to repeat a full treatment. A severe illness or worsening pain needs clinical assessment.
A single treatment does not end the care plan. Gonorrhea can recur through reinfection. CDC guidance recommends retesting about three months after treatment and a partner-management plan. Test-of-cure needs depend on the infection site, treatment and clinical circumstances; pharyngeal infection has a specific follow-up pathway and needs a regimen appropriate to that site. Ask for a dated plan that applies to the drug you actually received.
Ask whether the medicine is an appropriate available option for your infection and whether the pharmacy can fill the prescribed packet. FDA approval does not establish Nao stock, payer coverage or same-day dispensing. Confirm medication and visit/test costs separately. An alternative recommended treatment may be more appropriate; do not delay needed care solely to obtain a new oral product.
Nuzolvence is the oral antibiotic zoliflodacin, FDA-approved in December 2025 for uncomplicated urogenital gonorrhea. It is supplied as granules mixed into an oral suspension and taken as a single prescribed treatment. This indication is specific: it does not establish the medicine as treatment for throat, rectal or disseminated gonorrhea. A clinician must identify the infection sites and review safety before choosing it.
The labeled population includes adults and adolescents aged 12 or older weighing at least 35 kg with uncomplicated urogenital gonorrhea. A known allergy to the medicine and concurrent moderate or strong CYP3A4 inducers are contraindications. Pregnancy must be assessed: the label calls for a pregnancy test in patients who can become pregnant and warns of fetal harm based on animal data. Infection site, pregnancy, weight, interacting medicines and other treatment options affect the decision.
Tell the clinician about vaginal, oral and anal exposures and symptoms. Genital, throat and rectal tests may be needed. Fever, severe pelvic pain, testicular pain or a painful swollen joint requires assessment for complications.
Bring all prescription drugs, supplements and herbs. Discuss pregnancy testing, contraception and fertility concerns before treatment. A medicine that changes drug metabolism can make zoliflodacin unsuitable.
The prescribed treatment uses a single packet prepared with water. Food instructions depend on weight: patients from 35 to under 50 kg take it on an empty stomach, while those at least 50 kg take it with food. Follow the supplied instructions; do not substitute other liquids or estimate the dose.
Obtain a plan for any other infection detected, treatment of partners, avoiding sex during the post-treatment interval and retesting. Persistent symptoms require reassessment rather than another self-administered packet.
A single treatment does not end the care plan. Gonorrhea can recur through reinfection. CDC guidance recommends retesting about three months after treatment and a partner-management plan. Test-of-cure needs depend on the infection site, treatment and clinical circumstances; pharyngeal infection has a specific follow-up pathway and needs a regimen appropriate to that site. Ask for a dated plan that applies to the drug you actually received.
Nuzolvence's US indication is uncomplicated urogenital gonorrhea in eligible patients. It is not an approved substitute for chlamydia or Mycoplasma genitalium treatment. If another infection is detected, the clinician chooses its separate regimen and follow-up. Do not assume one oral packet treats every positive STI site or organism.
Blujepa is the oral antibiotic gepotidacin. Its uncomplicated urinary tract infection indication applies to eligible female patients; it is not a general remedy for every urinary symptom. Burning, urgency or frequent urination can come from a UTI, an STI or another condition. An evaluation establishes the diagnosis and whether this antibiotic is appropriate. Choosing a recently approved medicine does not remove the need to assess infection location, other treatments and safety.
For uncomplicated UTI, the US label covers female adults and adolescents aged 12 or older weighing at least 40 kg, with infection caused by the specified susceptible organisms. The gonorrhea indication begins at 45 kg and is limited to uncomplicated urogenital infection in patients with limited or no alternative options. Fever, flank pain, vomiting, pregnancy or systemic illness may change the diagnosis and treatment setting. A clinician reviews kidney and liver function, heart-rhythm risks and interacting medicines before prescribing.
Tell the clinician when symptoms began, whether there is fever, back or flank pain, discharge, pregnancy possibility or a recent sexual exposure. Bring prior urine cultures, antibiotic courses and information about resistance or allergies.
Urine tests and sometimes a culture help guide UTI care. STI testing may require a separate urine or swab specimen. A standard urine culture is not a substitute for a chlamydia/gonorrhea NAAT.
The review includes QT prolongation, heart rhythm, potassium, renal/hepatic status and the full drug list. Some interactions or organ impairment make Blujepa inappropriate. The higher gonorrhea regimen has additional restrictions, so safety rules cannot be borrowed between indications.
The labeled UTI course is oral treatment twice daily for five days with food. Your prescription supplies the actual dose and instructions. Arrange review if symptoms persist or return, and a plan to act on any culture result.
Feeling better early does not justify stopping the course without advice. A missed dose, vomiting after a dose or inability to obtain the full prescription needs pharmacist or clinician guidance; do not double a dose. Persistent symptoms may require culture review, examination or a different diagnosis. Repeated infections deserve a separate assessment rather than repeated assumptions that this medicine is the right preventive treatment.
Do not assume the medicine, laboratory work, administration, monitoring or follow-up is included in the evaluation fee. Ask for an itemized estimate and identify which charges go to the clinic, pharmacy or laboratory. An approved appointment benefit and an approved medication benefit can be separate decisions.
Choose the right appointment type to continue.
